- Home
- ANTX
as 05-30-2025 4:00pm EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 37.3M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 319.1K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $3.07 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
Business Wire
18 days ago
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Business Wire
a month ago
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Business Wire
a month ago
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
Simply Wall St.
2 months ago
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Business Wire
3 months ago
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
Simply Wall St.
3 months ago
Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring
Business Wire
3 months ago
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.